Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases. To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (α-thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres, were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n = 784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [3]
In the citing paper
“Indeed, the K27M mutation has been observed to occur in genes encoding all forms of histone H3 (H3.1, H3.2, and H3.3) in human glioma (1,10,24).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [1]
In the citing paper
“ALT is associated with mutations in the chromatin remodeller α-thalassaemia/mental retardation syndrome X-linked (AT R X ) both in vitro and in several human cancers, including glioblastomas162–165.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [163]
In the citing paper
“The H3.3G34R/V mutated tumours are found almost exclusively in the cerebral hemispheres 101,102 , whereas H3.1K27M tumours are restricted to an area of the brainstem called the pons and H3.3K27M tumours can also be found along the midline of the brain 106 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [106]
In the citing paper
“A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors, and results in a lysine-to-methionine substitution (H3K27M)2,3.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [2]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cited by
Items 701–800 of 1,001
Actionable Molecular Biomarkers in Primary Brain Tumors
Staedtke, V., Dzaye, O. D. A., & Holdhoff, M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.06.003 · Cited by 65
“Of particular clinical relevance are mutations in histone H3F3A, with 78% of DIPG harboring the amino acid substitution lysine 27 to methionine (K27M) and up to approximately onethird of non-brainstem HGGs carrying glycine 34 to valine or arginine (G34V/R) or K27M mutations [48,49].”
IκBζ: an emerging player in cancer
Willems, M., Dubois, N., Musumeci, L., Bours, V., & Robe, P. A. J. T. (2016) · Oncotarget · doi:10.18632/oncotarget.11624 · Cited by 62
“This epigenetic mechanism has a well known physiological role in the molecular cascades that regulates transcription of genes involved in primary and secondary inflammatory responses [69] and in cancer [70, 71].”
BackgroundEpigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma
Hashizume, R. (2017) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2017-0018 · Cited by 63
CAR T Cell Therapy for Pediatric Brain Tumors
Patterson, J. D., Henson, J. C., Breese, R. O., Bielamowicz, K., & Rodriguez, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01582 · Cited by 61
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation
Khadka, P., Reitman, Z. J., Lu, S. D., Buchan, G. B. J., Gionet, G. L., Dubois, F. P. B., Carvalho, D. M., Shih, J., Zhang, S., Greenwald, N. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28198-8 · Cited by 66
“In addition to the characteristic histone K27M mutations 1,2 , DMGs often alterations in the p53 pathway, including mutations in TP53 itself, as well as PPM1D , a regulator of p53 activity 3 – 6 .”
Chalil, A., & Ramaswamy, V. (2015) · Journal of Child Neurology · doi:10.1177/0883073815599259 · Cited by 61
“Histone H3 mutations mainly occur at lysine residue at position 27 (Lysine to methionine K27 M mutation) or at the glycine residue at position 34 (Glycine to valine G34 V or glycine to arginine G34 R mutations).38-41 K27 M mutations are often found in PHGG occurring in the brain stem (78% of DIPG cases), and midline t…”
BackgroundThe Role of Chromatin Remodeling in Medulloblastoma
Jones, D., Northcott, P. A., Kool, M., & Pfister, S. M. (2013) · Brain Pathology · doi:10.1111/bpa.12019 · Cited by 62
“3), as well as the histone chaperones ATRX and DAXX, have recently been identified in a subset of another malignant pediatric brain tumor—glioblastoma (33, 68, 81) (see also Brain Pathology ISSN 1015-6305”
BackgroundSelf-citationWeichenhan, D., & Plass, C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt348 · Cited by 65
“3-encoding gene H3F3A in pediatric glioblastoma (25).”
Self-citationThe epigenetics of tumour initiation: cancer stem cells and their chromatin
Avgustinova, A., & Benitah, S. A. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.01.003 · Cited by 58
The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells
Sui, A., Yongbing, X., Li, Y., Hu, Q., Wang, Z., Zhang, H., Yang, J., Guo, X., & Zhao, W. (2017) · Oncotarget · doi:10.18632/oncotarget.19793 · Cited by 58
Signaling pathways and mesenchymal transition in pediatric high-grade glioma
Meel, M. H., Schaper, S. A., Kaspers, G. J. L., & Hulleman, E. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2714-7 · Cited by 62
Molecular Rules Governing De Novo Methylation in Cancer
Nejman, D., Straussman, R., Steinfeld, I., Ruvolo, M., Roberts, D., Yakhini, Z., & Cedar, H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3042 · Cited by 54
Panditharatna, E., Yaeger, K., Kilburn, L. B., Packer, R. J., & Nazarian, J. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.04.008 · Cited by 62
“Specifically, ATRX mutations are more frequent in children diagnosed with DIPG at an older age [38].”
BackgroundInfluentialOkada, Y., & Yamaguchi, K. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2447-z · Cited by 60
“More recently, a lysinemethionine (K-M) mutation in histone H3 was identified from pediatric glioma patients [49, 50].”
BackgroundPediatric low-grade gliomas can be molecularly stratified for risk
Yang, R. R., Aibaidula, A., Wang, W., Chan, A. K., Shi, Z., Zhang, Z.-Y., Chan, D. T. M., Poon, W. S., Liu, X.-Z., Li, W.-C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1874-3 · Cited by 62
Self-citationNucleosome Dynamics as Modular Systems that Integrate DNA Damage and Repair
Peterson, C. L., & Almouzni, G. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012658 · Cited by 51
“3-specific chaperone (Jiao et al. 2011; Schwartzentruber et al. 2012).”
SETD2: from chromatin modifier to multipronged regulator of the genome and beyond
Molenaar, T. M., & van Leeuwen, F. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04352-9 · Cited by 61
Identification of epigenetic modulators as determinants of nuclear size and shape
Schibler, A., Jevtić, P., Pegoraro, G., Levy, D. L., & Misteli, T. (2023) · eLife · doi:10.7554/elife.80653 · Cited by 56
Metabolic Modulation of Epigenetics in Gliomas
Venneti, S., & Thompson, C. B. (2013) · Brain Pathology · doi:10.1111/bpa.12022 · Cited by 59
“Recent studies have emerged implicating histone modifications in adult glioblastomas (16, 32, 51) and mutations in genes encoding histone proteins in pediatric glioblastomas (25, 36, 40, 48).”
BackgroundDiffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers
Ichimura, K., Narita, Y., & Hawkins, C. E. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1439-7 · Cited by 64
“Somatic mutations of ATRX were first found in pancreatic neuroendocrine tumours [59], then in paediatric glioblastomas [125] and in astrocytomas [61].”
InfluentialSelf-citationWang, A., Jones, D., Abecassis, I. J., Cole, B., Leary, S. E. S., Lockwood, C. M., Chávez, L., Capper, D., Korshunov, A., Fallah, A., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0507 · Cited by 56
“The ATRX gene is a core component of a chromatin remodeling complex active in telomere function, the alteration of which results in alternative lengthening of telomeres, a presumed precursor to genomic instability, and a recognized contributor to gliomagenesis (62).”
BackgroundSelf-citationClinical trials for diffuse intrinsic pontine glioma: the current state of affairs
Rechberger, J. S., Lu, V. M., Zhang, L., Power, E. A., & Daniels, D. J. (2019) · Child s Nervous System · doi:10.1007/s00381-019-04363-1 · Cited by 56
Pathologic and molecular features of hepatocellular carcinoma: An update
Vij, M., & Caldéraro, J. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i4.393 · Cited by 56
Székvölgyi, L., Ohta, K., & Nicolas, A. G. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016527 · Cited by 60
“Mishaps in the proper writing, reading, and erasing of these biochemical tags can interfere with recombination, leading to the formation of pathological diseases, such as infertility or carcinogenesis (Schwartzentruber et al. 2012).”
BackgroundWEE1 tyrosine kinase, a novel epigenetic modifier
Mahajan, K. N., & Mahajan, N. P. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.02.003 · Cited by 61
Management of high-grade gliomas in the pediatric patient: Past, present, and future
Vanan, M., & Eisenstat, D. D. (2014) · Neuro-Oncology Practice · doi:10.1093/nop/npu022 · Cited by 69
“Whole exome-sequencing studies of pediatric GBM have identified mutations in a-thalassemia/ mental retardation syndrome X-linked (ATRX, 14%–29%)(54) and death domain-associated protein (DAXX, 34%) genes.(69) These genes act as histone chaperones and help in the chromosomal deposition of H3.”
BackgroundInfluentialThe good, the bad and the ugly: Epigenetic mechanisms in glioblastoma
Carén, H., Pollard, S. M., & Beck, S. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.007 · Cited by 62
Modifying Chromatin by Histone Tail Clipping
Azad, G. K., Swagatika, S., Kumawat, M., Kumawat, R., & Tomar, R. S. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.07.013 · Cited by 58
Xiong, C., Wen, Z., Yu, J., Chen, J., Liu, C.-P., Zhang, X., Chen, P., Xu, R.-M., & Li, G. (2018) · BMC Biology · doi:10.1186/s12915-018-0573-9 · Cited by 59
The clinical use of IDH1 and IDH2 mutations in gliomas
Pïcca, A., Berzero, G., Stefano, A. L. D., & Sanson, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1548935 · Cited by 60
“of glioblastoma, or an immunostaining positivity for the H3K27M mutation, as the two genetic alterations are known to be mutually exclusive [29].”
BackgroundDevelopmental origins and oncogenic pathways in malignant brain tumors
Lu, Q. R., Qian, L., & Zhou, X. (2019) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.342 · Cited by 60
“TP53 mutations have been identified in up to 40% of DIPGs and often co-occur with PDGFRA amplification (Grill et al., 2012; Puget et al., 2012; K. R. Taylor et al., 2014).”
BackgroundInfluentialTumor-Specific T Cell Activation in Malignant Brain Tumors
Mohme, M., & Neidert, M. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00205 · Cited by 58
Chen, K.-Y. M., Bush, K. M., Klein, R. H., Cervantes, V., Lewis, N., Naqvi, A., Carcaboso, A. M., Lechpammer, M., & Knoepfler, P. S. (2020) · Communications Biology · doi:10.1038/s42003-020-1076-0 · Cited by 58
Genetic Events That Shape the Cancer Epigenome
Ryan, R. J. H., & Bernstein, B. (2012) · Science · doi:10.1126/science.1223730 · Cited by 64
Histone variants: the tricksters of the chromatin world
Volle, C. B., & Dalal, Y. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.006 · Cited by 54
Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas
Udugama, M., Hii, L. L., Garvie, A., Cervini, M., Vinod, B., Chan, F. L., Das, P. P., Mann, J. R., Collas, P., Voon, H. P. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22543-z · Cited by 55
Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going?
Sloan, A. R., Silver, D. J., Kint, S., Gallo, M., & Lathia, J. D. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae011 · Cited by 58
Multifunctional histone variants in genome function
Wong, L. H., & Tremethick, D. J. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00759-1 · Cited by 59
“3 variant isoform, H3-3A 247–249 .”
Mur, P., Mollejo, M., Ruano, Y., de Lope, Á. R., Fiaño, C., García, J. F., Castresana, J. S., Hernández‐Laín, A., REY, J. A., & Meléndez, B. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1130-9 · Cited by 58
“Mutations in H3F3A, and in the genes coding for ATRX and DAXX proteins were detected in pediatric GBMs and were shown to be associated with TP53 mutations and alternative lengthening of telomeres (ALT) [43, 56].”
BackgroundClinical and molecular characteristics of congenital glioblastoma
Macy, M. E., Birks, D. K., Barton, V. N., Chan, M. H., Donson, A. M., Kleinschmidt-DeMasters, B. K., Bemis, L., Handler, M. H., & Foreman, N. K. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos125 · Cited by 55
“3 mutations found in pGBMs and diffuse pontine gliomas.(46,47) Although our sample size is small, with only 4 patients tested, and we did not test for other alterations in the chromatin remodeling complex; this may further support that cGBMs are biologically different from their pediatric and adult counterparts.”
BackgroundDelaney, K., Mailler, J., Wenda, J. M., Gabus, C., & Steiner, F. A. (2018) · Genetics · doi:10.1534/genetics.118.300909 · Cited by 57
“3 mutations have been identified as recurrent somatic driver mutations in gliomas and a subset of skeletal neoplasms (Schwartzentruber et al. 2012; Sturm et al. 2012; Wu et al. 2012; Behjati et al. 2013).”
BackgroundGenotype-targeted local therapy of glioma
Shankar, G. M., Kirtane, A. R., Miller, J. J., Mazdiyasni, H., Rogner, J., Tai, T., Williams, E. A., Higuchi, F., Juratli, T. A., Tateishi, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805751115 · Cited by 55
“3 ( H3F3A ) (3), and signaling kinase BRAF (4).”
InfluentialStructures and Functions of Chromatin Fibers
Chen, P., Li, W., & Li, G. (2021) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062920-063639 · Cited by 63
Carvalho, D. M., Richardson, P. J., Olaciregui, N., Stankunaite, R., Lavarino, C. E., Molinari, V., Corley, E. A., Smith, D. P., Ruddle, R. R., Donovan, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1201 · Cited by 58
“This tumor type comprises approximately 10% of all pediatric brain tumors, and outcomes remain poor, partly due to its unique biology, as evidenced by the high prevalence (>80%) of lysine-to-methionine substitutions at position 27 (K27M) in the H3F3A, HIST1H3B, and HIST1H3C genes (5, 6).”
BackgroundDiffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective
Perrone, M. G., Ruggiero, A., Centonze, A., Carrieri, A., Ferorelli, S., & Scilimati, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200806110206 · Cited by 59
The Genetic Signatures of Pediatric High-Grade Glioma: No Longer a One-Act Play
Diaz, A. K., & Baker, S. J. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.06.003 · Cited by 58
“TP53mutations occur in up to 35% of pNBS-HGGs (range: 18%-35%) and appear to be more common in DIPGs (40%50% of cases).(14,25,32,34,35,39-44,48,49) From the aforementioned data, we can conclude that although the 3 main signaling pathways affected in aHGG are also affected in pHGG, pediatric and adult tumors differ reg…”
InfluentialSingle cell analysis of Daxx and ATRX-dependent transcriptional repression
Newhart, A., Rafalska-Metcalf, I. U., Yang, T., Negorev, D. G., & Janicki, S. M. (2012) · Journal of Cell Science · doi:10.1242/jcs.110148 · Cited by 60
“3 acquires gain of function driver mutations in pediatric glioblastoma (Schwartzentruber et al., 2012; Wu et al., 2012) also supports the idea that it may be an active participant in cellular signaling events and not merely delivered passively to the nucleosome.”
BackgroundYadav, R. K., Jablonowski, C. M., Fernandez, A. G., Lowe, B. R., Henry, R. A., Finkelstein, D., Barnum, K. J., Pidoux, A. L., Kuo, Y., Huang, J., et al. (2017) · eLife · doi:10.7554/elife.27406 · Cited by 54
“Proteins that regulate chromatin dynamics are frequently mutated in cancer, and recently mutations in the histone genes themselves have been discovered (Schwartzentruber et al., 2012; Wu et al., 2012; Behjati et al., 2013).”
BackgroundLim, J., Park, J. H., Baude, A., Yoo, Y., Lee, Y. K., Schmidt, C. R., Park, J. B., Fellenberg, J., Zustin, J., Haller, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13887-y · Cited by 54
Self-citationOppel, F., Tao, T., Shi, H., Ross, K. N., Zimmerman, M. W., He, S., Tong, G., Aster, J. C., & Look, A. T. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008039 · Cited by 56
Boileau, M., Shirinian, M., Gayden, T., Harutyunyan, A. S., Chen, C. C. L., Mikael, L. G., Duncan, H. M., Neumann, A. L., Arreba-Tutusaus, P., Jay, N. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10705-z · Cited by 55
Self-citationBiomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review
Bocchini, M., Nicolini, F., Severi, S., Bongiovanni, A., Ibrahim, T., Simonetti, G., Grassi, I., & Mazza, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00831 · Cited by 58
The Multiple Facets of ATRX Protein
Valenzuela, M., Amato, R., Sgura, A., Antoccia, A., & Berardinelli, F. (2021) · Cancers · doi:10.3390/cancers13092211 · Cited by 54
H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape
Furth, N., Algranati, D., Dassa, B., Beresh, O., Fedyuk, V., Morris, N., Kasper, L. H., Jones, D. R., Monje, M., Baker, S. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110836 · Cited by 55
Self-citationH3K27M mutant glioma: Disease definition and biological underpinnings
Saratsis, A. M., Knowles, T., Petrović, A., & Nazarian, J. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad164 · Cited by 61
PHF6 Degrees of Separation: The Multifaceted Roles of a Chromatin Adaptor Protein
Todd, M. A. M., Ivanochko, D., & Picketts, D. J. (2015) · Genes · doi:10.3390/genes6020325 · Cited by 57
“, MECP2) [4–8].”
Mangerel, J., Price, A. J., Castelo‐Branco, P., Brzezinski, J. J., Buczkowicz, P., Rakopoulos, P., Merino, D. M., Baskin, B., Wasserman, J. D., Mistry, M., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1348-1 · Cited by 56
“3 (the product of the H3f3a gene) at the telomeres, favoring formation of heterochromatin [30, 44].”
BackgroundInfluentialSelf-citationIdentification of FoxR2 as an Oncogene in Medulloblastoma
Koso, H., Tsuhako, A., Lyons, E., Ward, J. M., Rust, A. G., Adams, D. J., Jenkins, N. A., Copeland, N. G., & Watanabe, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1523 · Cited by 56
Moniz, S., Martinho, O., Pinto, F., Sousa, B., Loureiro, C. A., Oliveira, M. J., Moita, L. F., Honavar, M., Pinheiro, C., Pires, M. M., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds405 · Cited by 52
Biomarker-based prognostic stratification of young adult glioblastoma
Zhang, R.-Q., Shi, Z., Chen, H., Chung, N. Y., Yin, Z., Li, K. K., Chan, D. T. M., Poon, W. S., Wu, J., Zhou, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5456 · Cited by 55
The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours
Pipinikas, C., Berner, A., Sposito, T., & Thirlwell, C. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0175 · Cited by 55
Genomics of adult and pediatric solid tumors.
Rahal, Z., Abdulhai, F., Kadara, H. N., & Saab, R. H. (2018) · Europe PMC (PubMed Central) · Cited by 58
DeWire-Schottmiller, M. D., Fuller, C. E., Hummel, T. R., Chow, L. M. L., Salloum, R., de Blank, P. M. K., Pater, L. E., Lawson, S. A., Zhu, X., Dexheimer, P. J., et al. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03641-2 · Cited by 61
Chaouch, A., Berlandi, J., Chen, C. C. L., Frey, F., Badini, S., Harutyunyan, A. S., Chen, X., Krug, B., Hébert, S., Jeibmann, A., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.10.008 · Cited by 55
Self-citationSplicing is an alternate oncogenic pathway activation mechanism in glioma
Siddaway, R., Milos, S., Vadivel, A. K. A., Dobson, T., Swaminathan, J., Ryall, S. T., Pajovic, S., Patel, P. G., Nazarian, J., Becher, O. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28253-4 · Cited by 64
Hummel, T. R., Salloum, R., Drissi, R., Kumar, S. S., Sobo, M., Goldman, S., Pai, A. L. H., Leach, J., Lane, A., Pruitt, D. W., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2008-6 · Cited by 52
“cally and biologically distinct subgroup of DIPG associated with shorter survival [35].”
BackgroundRare allelic forms of PRDM9 associated with childhood leukemogenesis
Hussin, J., Sinnett, D., Casals, F., Idaghdour, Y., Bruat, V., Saillour, V., Healy, J., Grenier, J., de Malliard, T., Busche, S., et al. (2012) · Genome Research · doi:10.1101/gr.144188.112 · Cited by 57
“2005), is a histone methylation event misregulated in many pediatric cancers (Schwartzentruber et al. 2012; Wu et al. 2012; Zhang et al. 2012) and has been linked to leukemia initiation (Chi et al.”
BackgroundNoberini, R., Robusti, G., & Bonaldi, T. (2021) · FEBS Journal · doi:10.1111/febs.15707 · Cited by 57
Udugama, M., Vinod, B., Chan, F. L., Hii, L. L., Garvie, A., Collas, P., Kalitsis, P., Steer, D. L., Das, P. P., Tripathi, P., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac259 · Cited by 52
Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM
Pathak, P., Jha, P., Purkait, S., Sharma, V., Suri, V. S., Sharma, M. C., Faruq, M., Suri, A., & Sarkar, C. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1675-z · Cited by 54
“3 (H3F3A gene) at two critical positions within the histone tail namely K27M and G34V/R [5].”
BackgroundInfluentialCancer genomics identifies disrupted epigenetic genes
Simó‐Riudalbas, L., & Esteller, M. (2013) · Human Genetics · doi:10.1007/s00439-013-1373-5 · Cited by 53
Zhou, B., Li, Y., Deng, Q., Wang, H., Wang, Y., Cai, B., & Han, Z. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1641-7 · Cited by 51
“At molecular or cellular levels, factors that cause cancer include gene mutations [1, 2], genomic instability [3, 4], and deregulation in mechanisms that maintain a balance between cellular growth, proliferation, differentiation, and apoptosis [5].”
BackgroundEvidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours
Nguyễn, A. T., Colin, C., Nanni‐Metellus, I., Padovani, L., Maurage, C., Varlet, P., Miquel, C., Uro‐Coste, E., Godfraind, C., Lechapt, E., et al. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12196 · Cited by 52
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms
Carroll, S. L. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.10.023 · Cited by 56
Distinct molecular profile of diffuse cerebellar gliomas
Nomura, M., Mukasa, A., Nagae, G., Yamamoto, S., Tatsuno, K., Ueda, H., Fukuda, S., Umeda, T., Suzuki, T., Otani, R., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1771-1 · Cited by 54
“3, is predominantly found in pediatric and young adult high-grade gliomas located in a midline structure such as the brainstem, thalamus, or spinal cord, whereas the G34R/V mutation is associated with adolescent glioblastoma (GBM) in cerebral hemispheres [2, 16, 43, 48].”
BackgroundSelf-citationBroniscer, A., Jia, S., Mandrell, B. N., Hamideh, D., Huang, J., Onar‐Thomas, A., Gajjar, A. J., Raimondi, S. C., Tatevossian, R., & Stewart, C. F. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27035 · Cited by 54
Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma
Cho, H. J., Zhao, J., Jung, S. W., Ladewig, E., Kong, D., Suh, Y., Lee, Y., Kim, D., Ahn, S. H., Bordyuh, M., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy123 · Cited by 56
Invited Review: DNA methylation‐based classification of paediatric brain tumours
Pérez, E., & Capper, D. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12598 · Cited by 53
Drugging histone methyltransferases in cancer
Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 51
Kluiver, T. A., Alieva, M., van Vuurden, D. G., Wehrens, E. J., & Rios, A. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00092 · Cited by 59
The H3K36me2 writer-reader dependency in H3K27M-DIPG
Yu, J.-R., LeRoy, G., Bready, D., Frenster, J. D., Saldaña-Meyer, R., Jin, Y., Descostes, N., Stafford, J. M., Placantonakis, D. G., & Reinberg, D. (2021) · Science Advances · doi:10.1126/sciadv.abg7444 · Cited by 53
Kurokawa, R., Baba, A., Kurokawa, M., Pinarbasi, E. S., Makise, N., Ota, Y., Kim, J., Srinivasan, A., & Moritani, T. (2021) · Journal of Neuroimaging · doi:10.1111/jon.12939 · Cited by 51
Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers
Arcella, A., Limanaqi, F., Ferese, R., Biagioni, F., Oliva, M. A., Storto, M., Fanelli, M., Gambardella, S., & Fornai, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020685 · Cited by 53
Slatter, T. L., Hsia, H., Samaranayaka, A., Sykes, P. H., Clow, W. M., Devenish, C. J., Sutton, T., Royds, J. A., Ip, P. P. C., Cheung, A., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.11 · Cited by 52
Epigenetic biomarkers: A new perspective in laboratory diagnostics
García‐Giménez, J. L., Sanchis‐Gomar, F., Lippi, G., Mena, S., Ivars, D., Gómez‐Cabrera, M. C., Viña, J., & Pallardó, F. V. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.05.021 · Cited by 50
“Thus, the analysis of mutations of histone and histone variants may be a useful tool for identifying several diseases and unveil their pathogenesis sincemutations on histones and their histone variants can change the functionality of these proteins [42].”
BackgroundGliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas
Broniscer, A., Chamdine, O., Hwang, S. N., Lin, T., Pounds, S. B., Onar‐Thomas, A., Shurtleff, S. A., Allen, S. J., Gajjar, A. J., Northcott, P. A., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1532-y · Cited by 55
“Other amplified oncogenes included MDM4 (n = 2), CDK4 (n = 1), MYC (n = 1), and MYCN (n = 1).”
InfluentialClinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas
Siegal, T. (2015) · Advances and technical standards in neurosurgery · doi:10.1007/978-3-319-21359-0_4 · Cited by 52
Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults
Rodríguez, F. J., Vizcaíno, M. A., & Lin, M. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.05.005 · Cited by 52
Maury, E., & Hashizume, R. (2017) · Epigenetics · doi:10.1080/15592294.2016.1278095 · Cited by 52
Lam, S. K., Lin, Y., Zinn, P. O., Su, J. M. F., & Pan, I.-W. E. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.10.041 · Cited by 54
Significance of TERT and ATRX mutations in glioma
Liu, J., Zhang, X., Xiao-ling, Y. A. N., Sun, M., Fan, Y., & Huang, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9634 · Cited by 54
“Similar to TERT promoter mutations, ATRX mutations are also associated with mutations in the tumor suppressor gene p53 (31); ATRX regulates the upstream pathways of cancer by modulating p53 (32).”
BackgroundHistone H3.3 mutation in giant cell tumor of bone: an update in pathology
Yamamoto, H., Ishihara, S., Toda, Y., & Oda, Y. (2019) · Medical Molecular Morphology · doi:10.1007/s00795-019-00238-1 · Cited by 50
Gehre, M., Bunina, D., Sidoli, S., Lübke, M. J., Diaz, N. S., Trovato, M., Garcia, B. A., Zaugg, J. B., & Noh, K. (2020) · Nature Genetics · doi:10.1038/s41588-020-0586-5 · Cited by 59
Chintagumpala, M., & Gajjar, A. J. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.011 · Cited by 51
“H3 mutations occur exclusively in approximately 38% of childhood, and young adult patients with HGG and are mutually exclusive with respect to mutations in IDH1.(37,39) Mutations in H3F3A, which result in”
BackgroundInfluentialTherapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms
Cruceru, M. L., Neagu, M. T., Demoulin, J., & Constantinescu, S. N. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12122 · Cited by 56
Tafessu, A., O’Hara, R. A., Martire, S., Dube, A. L., Saha, P., Gant, V. U., & Banaszynski, L. A. (2023) · Genome biology · doi:10.1186/s13059-023-02867-3 · Cited by 53
Developmental origins shape the paediatric cancer genome
Chen, X., Yang, W., Roberts, C. W. M., & Zhang, J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00684-9 · Cited by 56
“Similarly, the common subtypes of acute lymphoblastic leukaemia (ALL) in children — that is, those that harbour a ETV6 – RUNX1 (ETS translocation variant 6 – runt-related transcription factor 1) gene fusion or exhibit hyperdiploidy — are rarely seen in adults.”
InfluentialEid, R., Demattei, M.-V., Episkopou, H., Augé‐Gouillou, C., Decottignies, A., Grandin, N., & Charbonneau, M. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01317-14 · Cited by 56
Incorporation of histone H3.1 suppresses the lineage potential of skeletal muscle
Harada, A., Maehara, K., Sato, Y., Konno, D., Tachibana, T., Kimurâ, H., & Ohkawa, Y. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1346 · Cited by 52
“3) are associated with human pediatric glioblastoma (11) and are also known to cause abnormal heterochromatin formation in mouse embryos (12).”
BackgroundLutsik, P., Baude, A., Mancarella, D., Öz, S., Kühn, A., Tóth, R., Hey, J., Toprak, U. H., Lim, J., Nguyễn, V. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18955-y · Cited by 51
“3-G34R/V) in pediatric gliomas 9 , as well as glycine-34-to-tryptophan or leucine (H3.”
Self-citation
Metadata
- Authors
- Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., Korbel, J. O., Hielscher, T., Hauser, P., Garami, M., Klekner, A., Bognar, L., Ebinger, M., Schuhmann, M. U., Scheurlen, W., Pekrun, A., Frühwald, M. C., Roggendorf, W., Kramm, C., Dürken, M., Atkinson, J., Lepage, P., Montpetit, A., Zakrzewska, M., Zakrzewski, K., Liberski, P. P., Dong, Z., Siegel, P., Kulozik, A. E., Zapatka, M., Guha, A., Malkin, D., Felsberg, J., Reifenberger, G., von Deimling, A., Ichimura, K., Collins, V. P., Witt, H., Milde, T., Witt, O., Zhang, C., Castelo-Branco, P., Lichter, P., Faury, D., Tabori, U., Plass, C., Majewski, J., Pfister, S. M., & Jabado, N.
- Affiliations
- McGill University and Génome Québec Innovation Centre (CA)
- German Cancer Research Center (DE)
- McGill University (CA)
- Montreal Children's Hospital (CA)
- European Molecular Biology Laboratory (DE)
- Burdenko Neurosurgery Institute (RU)
- University Children's Hospital Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Cnopf´sche Kinderklinik (DE)
- Prof. Hess Kinderklinik (DE)
- University Hospital Augsburg (DE)
- University of Würzburg (DE)
- University Hospital in Halle (DE)
- Medical University of Lodz (PL)
- University Hospital Heidelberg (DE)
- University of Toronto (CA)
- Heinrich Heine University Düsseldorf (DE)
- University of Cambridge (GB)
- McGill University Health Centre (CA)
- Corresponding author
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- ORCID
- Schwartzentruber, Jeremy
- Korshunov, Andrey
- Jones, David T. W.
- Pfaff, Elke
- Sturm, Dominik
- Hovestadt, Volker
- Albrecht, Steffen
- Kool, Marcel
- Lindroth, Anders
- Jäger, Natalie
- Rausch, Tobias
- Ryzhova, Marina
- Korbel, Jan O.
- Hielscher, Thomas
- Ebinger, Martin
- Schuhmann, Martin U.
- Frühwald, Michael C.
- Dürken, Matthias
- Atkinson, Jeffrey
- Lepage, Pierre
- Zakrzewska, Magdalena
- Liberski, Pawel P.
- Siegel, Peter
- Kulozik, Andreas E.
- Zapatka, Marc
- Guha, Abhijit
- Malkin, David
- Felsberg, Jörg
- Reifenberger, Guido
- Ichimura, Koichi
- Collins, V. Peter
- Witt, Hendrik
- Milde, Till
- Witt, Olaf
- Zhang, Cindy
- Lichter, Peter
- Faury, Damien
- Tabori, Uri
- Plass, Christoph
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- Venue
- Nature
- Published
- 2012-01-29
- Volume
- 482
- Issue
- 7384
- Pages
- 226-231
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2158233796
- Cited by
- 2,631
- References
- 35
- Citations by year
- 2026: 109 · 2025: 138 · 2024: 188 · 2023: 189 · 2022: 200 · 2021: 226 · 2020: 238 · 2019: 188 · 2018: 166 · 2017: 200 · 2016: 174 · 2015: 165 · 2014: 189 · 2013: 166 · 2012: 90
- FWCI
- 92.99
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-03-28)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- NPARC (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Funders
- Cancer Research Institute
- Genome Canada
- Brain Tumour Charity (10/106)
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- H3F3A mutation, histone H3.3, ATRX mutation, chromatin remodeling, somatic mutations, TP53 mutation, H3K27M mutation, histone modifications, histone deacetylase inhibitors
- MeSH terms
- X-linked Nuclear Protein, Base Sequence, Child, Chromatin, DNA Mutational Analysis, DNA Helicases, Glioblastoma, Histones, Humans, Molecular Sequence Data, Mutation, Nuclear Proteins, Tumor Suppressor Protein p53, Telomere, Molecular Chaperones, Gene Expression Profiling, Chromatin Assembly and Disassembly, Adaptor Proteins, Signal Transducing, Co-Repressor Proteins, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.